Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Before the Bell Scans of Mylan, Forest Laboratories, Avanir Pharma, Akorn, and Medicines Co.



Before the Bell Scans of Mylan, Forest Laboratories, Avanir Pharma, Akorn, and
                                Medicines Co.

PR Newswire

LONDON, March 8, 2013

LONDON, March 8, 2013 /PRNewswire/ --

The U.S. Supreme Court last year upheld President Obama's Affordable Care Act
(ACA). The ACA is the biggest overhaul of the healthcare industry in decades.
While critics say that ACA will have a negative impact on the healthcare
industry, supporters of the reform believe that the increase in the amount of
insured individuals will ultimately benefit the industry. Apart from ACA,
another major trend that is having an impact on drug makers such as Mylan Inc.
(NASDAQ: MYL), Forest Laboratories Inc. (NYSE: FRX), Avanir Pharmaceuticals
Inc. (NASDAQ: AVNR), Akorn Inc. (NASDAQ: AKRX) and The Medicines Company
(NASDAQ: MDCO) is the expiration of patents on several blockbuster drugs. On
Thursday, drug makers ended on a mixed note even as the broad market rallied.
StockCall has taken an interest in these companies and you can now sign up to
download the free technical research on MYL, FRX, AVNR, AKRX, and MDCO at

http://www.stockcall.com/registration  

Shares of Mylan Inc. slipped in trading on Thursday. However, losses were
limited. The stock slipped after hitting a 52-week high of $31 in Thursday's
trading session. Mylan's shares closed 0.36% lower at $30.79 on above average
volume of 5.74 million. Shares of MYL have had an excellent run so far this
year, gaining more than 12%, compared to a gain of more than 8.20% for the S&P
500. The drug maker company's shares have recently broken through $29
resistance level, which is a bullish signal. The stock is also trading above
its 50-day and 200-day moving averages, which further confirms the bullish
trend. Sign up today to read the free research report on MYL at

http://www.StockCall.com/MYL030813.pdf  

Forest Laboratories Inc.'s shares rose in Thursday's trading session; however,
the gains were limited. The stock closed 0.24% higher at $37.38 on volume of
1.35 million. The company's shares are currently trading close to their
52-week high of $38.45. Year-to-date, the stock has underperformed the broad
market, gaining nearly 6%, compared to a gain of more than 8.20% for the S&P
500. Forest Laboratories shares are currently trading above their 50-day and
200-day moving averages, which is a bullish signal. The bullish trend is
further confirmed by the stock's MACD chart. Register to download the free
technical analysis on FRX at

http://www.StockCall.com/FRX030813.pdf  

Shares of Avanir Pharmaceuticals Inc. rose more than 1% in Thursday's trading
session, extending its gains for the week. The stock closed 1.01% higher at
$2.99 on Thursday and has now gained more than 7.50% in the last three
sessions. Year-to-date, the stock has now gained more than 14.20%. Avanir
Pharma's shares have recently broken through $2.80 resistance level, which is
a bullish signal. The stock has also crossed its 50-day moving average, which
further confirms the bullish trend. The stock's MACD has just crossed above
the signal line. Free report on AVNR can be accessed by registering at

http://www.StockCall.com/AVNR030813.pdf  

Shares of Akorn Inc. ended marginally higher in Thursday's trading session.
The stock closed 0.36% higher at $13.87 on volume of 234,270. Year-to-date,
the stock has gained more than 3.80%. Akorn's shares are currently facing
resistance at around $14. Register with StockCall and download the research on
AKRX for free at

http://www.StockCall.com/AKRX030813.pdf  

Shares of The Medicines Company fell sharply in Thursday's trading session.
The stock closed 1.64% lower at $31.70 on above average volume of 797,089.
Year-to-date, the stock has gained more than 32%, outperforming the broad
market. Read the full free research on MDCO by signing up to StockCall at

http://www.StockCall.com/MDCO030813.pdf  

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1-(646)-396-9857 (9:00 am EST - 01:30 pm EST)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement